Prescription Required.
Is the active pharmaceutical ingredient (api).
Treatment of intermediate or highrisk myelofibrosis (MF), including primary myelofibrosis (PMF), post-polycythemia vera MF, and post-essential thrombocythemia MF.
Treatment of steroidrefractory acute graft-versus-host disease (GvHD).
Jakavi 5mg Tab (Ruxolitinib) is a selective Janus kinase (JAK) inhibitor. It works by inhibiting the activity of JAK1 and JAK2 enzymes, which are involved in cytokine signaling pathways that contribute to the pathophysiology of myelofibrosis and GvHD. By blocking these pathways, ruxolitinib reduces inflammation, splenomegaly, and other symptoms associated with these conditions.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.
Dosage and frequency will be determined by your physician based on your condition and response to treatment.
Typically administered orally, twice daily with or without food.
Anemia
Thrombocytopenia (low platelet count)
Neutropenia (low neutrophil count)
Nausea
Vomiting
Diarrhea
Fatigue
Headache
Infection
Elevated liver enzymes
Peripheral edema (swelling)
Shortness of breath
Increased risk of bleeding and bruising
Consult your doctor. Alcohol may interact with ruxolitinib or worsen side effects.
Ruxolitinib may cause dizziness or fatigue. Avoid driving or operating machinery if affected.
Not recommended during pregnancy or breastfeeding unless the potential benefit outweighs the risk. Discuss with your doctor.
Not recommended for use in children unless specifically prescribed by a physician.
May require dose adjustment in patients with kidney impairment.
May require dose adjustment in patients with liver impairment.
Your doctor or pharmacist
The prescribing information (package insert) for your specific ruxolitinib formulation
Reputable medical websites such as the FDA or National Institutes of Health
